225110-25-8
Chemical Structure
(+)-(3R,8S)-Falcarindiol
Synonym(s): (3R,8S)-Falcarindiol; 3(R),8(S),9(Z)-Falcarindiol
- CAS No.: 225110-25-8
- Formula:C17H24O2
- Molecular Weight:260.37
IUPAC Name: (3R,8S,Z)-heptadeca-1,9-dien-4,6-diyne-3,8-diol
InChIKey: QWCNQXNAFCBLLV-YWALDVPYSA-N
SMILES: C=C[C@@H](O)C#CC#C[C@@H](O)/C=C\CCCCCCC
Biological Activity: (+)-(3R,8S)-Falcarindiol ((3R,8S)-Falcarindiol; 3 (R),8 (S),9 (Z)-Falcarindiol) is an orally active polyacetylene anti-mycobacterial agent. (+)-(3R,8S)-Falcarindiol exhibits antibacterial activity against Gram-positive bacteria, Gram-negative bacteria and mycobacteria. Co-administration of (+)-(3R,8S)-Falcarindiol with (3R)-falcarinol alters the composition of gut microbiota, reduces colonic tumor lesions and slows down polyp growth. (+)-(3R,8S)-Falcarindiol can be used in research related to tuberculosis and colorectal cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(+)-(3R,8S)-Falcarindiol | 98.53% | (+)-(3R,8S)-Falcarindiol ((3R,8S)-Falcarindiol; 3 (R),8 (S),9 (Z)-Falcarindiol) is an orally active polyacetylene anti-mycobacterial agent. (+)-(3R,8S)-Falcarindiol exhibits antibacterial activity against Gram-positive bacteria, Gram-negative bacteria and mycobacteria. Co-administration of (+)-(3R,8S)-Falcarindiol with (3R)-falcarinol alters the composition of gut microbiota, reduces colonic tumor lesions and slows down polyp growth. (+)-(3R,8S)-Falcarindiol can be used in research related to tuberculosis and colorectal cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. O'Neill T, et al. The Canadian medicinal plant Heracleum maximum contains antimycobacterial diynes and furanocoumarins. J Ethnopharmacol. 2013;147(1):232-237. [Content Brief]
- [2]. Kobaek-Larsen M, et al. Effect of the dietary polyacetylenes falcarinol and falcarindiol on the gut microbiota composition in a rat model of colorectal cancer. BMC Res Notes. 2018;11(1):411. Published 2018 Jun 27. [Content Brief]
